Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01154933 · ClinicalTrials.gov registry record · Phase 2
Exeantide in Type 2 Diabetes on Insulin
A Phase 2 study, sponsored by University at Buffalo.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT01154933 is a Phase 2 study that has completed, run by University at Buffalo. The registered enrollment target is 24 participants.
The verdict
NCT01154933, a Phase 2 study, has completed, sponsored by University at Buffalo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
Exenatide has been shown to result in better glycemic control in type II diabetes patients. Obesity and diabetes are states of increased inflammation; exenatide is expected to lead to decreased inflammation by virtue of better glycemic control and weight loss. The purpose of this study is to determine if the addition of Exenatide to diabetic patients will reduce the requirements of insulin particularly the short acting insulin. Exenatide may also lead to decreased inflammation by virtue of better glycemic control and weight loss, or an independent effect.
Interventions
- DRUG placebo
- DRUG exenatide 5 mcg
- DRUG exenatide 10 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2008-04 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01154933
The ClinicalTrials.gov registry entry for NCT01154933 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University at Buffalo, which has 67 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01154933 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01154933 about?
NCT01154933 is a clinical study titled "Exeantide in Type 2 Diabetes on Insulin". Exenatide has been shown to result in better glycemic control in type II diabetes patients. Obesity and diabetes are states of increased inflammation; exenatide is expected to lead to decreased inflammation by virtue of better glycemic control and weight loss. The purpose of this study is to determ...
What is the current status of trial NCT01154933?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2008-04. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01154933?
The interventions under investigation include: placebo (DRUG), exenatide 5 mcg (DRUG), exenatide 10 mcg (DRUG).
Who is sponsoring clinical trial NCT01154933?
This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.